BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Drug Development

  Tocagen Presents Updated Durable Complete Response Data from Phase I Trial of Toca 511 & Toca FC in Recurrent High-Grade Glioma

  Tocagen today reported updated data demonstrating long-term durable responses, and the conversion of initial partial responses into complete responses, from a Phase I study of Tocagen’s investigational product, Toca 511 & Toca FC, for the treatment of patients with recurrent high-grade glioma.

  October 27, 2017

   · 

  7 min read
• Biotech Bay

  Eiger BioPharma Announces Pricing of Public Offering of Common Stock

  Eiger BioPharma today announced the pricing of its underwritten public offering of 1,854,749 shares of its common stock at a price of $10.00 per share, before underwriting discounts and commissions.

  October 27, 2017

   · 

  3 min read
• Pharm Country

  Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

  The SUNBEAM study evaluated two doses (1 mg and 0.5 mg) of oral ozanimod in 1,346 patients with RMS in 20 countries treated for at least one year.

  October 27, 2017

   · 

  8 min read
• 

  Zebra Medical Vision Wants to Offer AI-Assisted Imaging Scans for $1

  This is another step in the company’s quest to provide high quality, affordable care to the world’s population.

  October 27, 2017

   · 

  3 min read
• Genetown

  Treatment Effects Maintained Over Five Years in Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme’s Lemtrada (Alemtuzumab) in Extension Study After Switching from Interferon Beta-1a

  These investigational data are being presented during the 7th Joint Meeting of the European and Americas Committees for Research and Treatment in Multiple Sclerosis (ECTRIMS-ACTRIMS).

  October 27, 2017

   · 

  15 min read
• Drug Development

  Epizyme Presents Data from a Phase I Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  First presentation of pediatric dose escalation data in tazemetostat, showing favorable safety and tolerability with promising anti-tumor activity.

  October 27, 2017

   · 

  6 min read
• Pharm Country

  Celsion Corporation Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock

  The closing of this offering is expected to take place on or about October 31, 2017.

  October 27, 2017

   · 

  3 min read
• Business

  CareDx to Announce Third Quarter 2017 Financial Results on November 9, 2017

  The CEO and CFO will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.

  October 27, 2017

   · 

  1 min read
• Drug Development

  Anavex Life Sciences Announces New Data Related to Multiple Sclerosis

  The data was presented in an oral presentation by the lead investigator, Robert Lisak, MD.

  October 27, 2017

   · 

  4 min read
• Business

  Clinipace Worldwide Executive Joins Board of Kidney Health Initiative

  Corley will serve on the Board for a renewable three-year term from January 1, 2018, to December 31, 2020.

  October 27, 2017

   · 

  1 min read